Table 1.
Clinical features
| RMC (n=33) | CDC (n=38) | FH-deficient RCC (n=29) | p-value | ||
|---|---|---|---|---|---|
| Median age (range) | 27.0 (10–63) | 65.5 (16–83) | 45.0 (18–71) | << 0.001 | |
| Male: Female | 2.6: 1 | 3.2: 1 | 3.1: 1 | 0.958 | |
| Race | Caucasian African-American Other |
9% (3/32) 78% (25/32) 13% (4/32) |
90% (28/31) 7% (2/31) 3% (1/31) |
71% (17/24) 12% (3/24) 17% (4/24) |
NA |
| Sickle cell disorder | 100%* | 0% | 0% | NA | |
| Family history of HLRCC or RCC (H) / HLRCC stigmata (S) | 0% | 0% | H: 39% (7/18) S: 29% (5/17) |
NA | |
| Laterality** | 75% (24/32) | 44% (14/32) | 43% (12/28) | < 0.0167 | |
| Tumor size cm (range) | 6.4 (4–12) | 6.3 (2–15.8) | 8.5 (3–18) | < 0.05 | |
| pT stage category | pT1–2 pT3–4 |
15% (5/33) 85% (27/33) |
9% (3/34) 91% (31/34) |
25% (7/28) 75% (21/28) |
0.225 |
| Local recurrence | 14% (4/29) | 23% (5/22) | 15% (3/20) | 0.723 | |
| Lymph node metastasis | 96% (25/26) | 48% (13/27) | 58% (15/26) | < 0.0167 | |
| Systemic metastasis | 94% (30/32) | 73% (16/22) | 65% (17/26) | 0.0169 | |
| Metastasis at presentation | 70% (19/27) | 47% (7/15) | 46% (6/13) | 0.194 | |
| Dead of disease mean time to death (month); range |
83% (24/29) 10.3; 7days– 25 |
61% (14/23) 11.6; 2.5– 37 |
61% (14/23) 18.6; 2– 64 |
0.145 | |
*
The history of sickle cell trait sickle cell hemoglobinopathy was unavailable in 18% (6/33), however, histological sickled erythrocytes were seen.
**
predilection for right kidney. NA, not analyzed.